Lupin is currently trading at Rs. 1933.30, down by 22.05 points or 1.13% from its previous closing of Rs. 1955.35 on the BSE.

The scrip opened at Rs. 1950.00 and has touched a high and low of Rs. 1957.20 and Rs. 1927.65 respectively. So far 10085 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1767.20 on 22-Jul-2024.

Last one week high and low of the scrip stood at Rs. 1961.10 and Rs. 1888.05 respectively. The current market cap of the company is Rs. 88302.96 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.

United States Food and Drug Administration (USFDA) has concluded inspection at Lupin’s Pithampur Unit-2 manufacturing facility. The inspection closed with the issuance of a Form-483 with four observations. The said inspection was conducted from July 08, 2025 to July 17, 2025. 

The company is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe. It upholds quality and compliance with utmost importance and is committed to be compliant with CGMP quality standards across all its facilities. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.